Check out Complete Prescribing Facts OPDIVO® (nivolumab) is indicated for the treatment of adult patients with classical Hodgkin lymphoma (cHL) that has relapsed or progressed after autologous hematopoietic stem mobile transplantation (HSCT) and brentuximab vedotin or immediately after 3 or maybe more traces of systemic therapy that includes autol